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Large numbers of patients referred for evaluation of chest pain
are unable to perform adequate, diagnostic exercise testing. In
these patients, dobutamine stress echocardiography (DSE) repre-
sents an alternative, exercise-independent stress modality. Apart
from the ;5% of patients with an inadequate acoustic window,
10% of patients referred for this test have nondiagnostic (sub-
maximal negative) test results. Serious side effects during or
shortly after DSE are uncommon, with ventricular fibrillation or
myocardial infarction occurring in ;1 of 2,000 studies. No deaths
have been reported. On the basis of a total number of 2,246
patients, reported in 28 studies, the sensitivity, specificity and
accuracy of the test for the detection of coronary artery disease
(CAD) were 80%, 84% and 81%, respectively. Mean sensitivities
for one-, two- and three-vessel disease were 74%, 86% and 92%,
respectively. The sensitivity for detection of disease in the left
circumflex coronary artery (55%) was lower, both compared with
that for left anterior descending (72%) and right coronary artery
disease (76%). The sensitivity of predicting multivessel disease
by multiregion echocardiographic abnormalities varied widely,
from 8% to 71%. In direct comparisons, DSE was superior to
exercise electrocardiography and dipyridamole echocardiography
and comparable to exercise echocardiography and radionuclide
imaging. DSE is a useful, feasible and safe exercise-independent
stress modality for assessing the presence, localization and extent
of CAD.
(J Am Coll Cardiol 1997;30:595–606)
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Confirming or excluding coronary artery disease (CAD) in
patients with chest pain remains a challenge because this
disease is still the leading cause of death in the Western world
(1). Traditionally, exercise electrocardiography is performed as
a first-line noninvasive diagnostic stress test (2). However,
large numbers of patients referred for evaluation of chest pain
are unable to perform adequate diagnostic exercise testing,
mainly because of deconditioning or neurologic, respiratory,
peripheral vascular or orthopedic limitations (3). In these
patients, dobutamine stress echocardiography (DSE) repre-
sents an alternative, exercise-independent stress modality.
Since its clinical introduction a decade ago (4), DSE has
become an established method for the diagnosis of CAD
(5–32). This review article deals with (1) methodologic aspects,
and (2) clinical applications of DSE to assess the presence,
localization and extent of CAD.
Methods and Statistical Analysis
We reviewed all DSE studies published in the major
English language journals up to August 1996 that met defined
criteria with respect to diagnostic accuracy for the detection of
CAD. These criteria were 1) inclusion of patients both with
and without angiographically defined CAD; and 2) statement
of how many patients with and without CAD had negative and
positive DSE results. Reports indicating that the patients
included were subsets of larger published studies were ex-
cluded. Also excluded from the primary diagnostic analysis
were studies solely involving patients with a myocardial infarc-
tion (MI) because the diagnosis of CAD is already established
in these patients. When DSE was compared with other stress
modalities, only those studies making direct comparisons in the
same patients were included.
Sensitivity was defined as the number of true positive tests
divided by the total number of patients with angiographically
significant CAD. Specificity was defined as the number of true
negative tests divided by the total number of patients without
angiographically significant CAD. Accuracy was defined by the
total number of true positive and true negative tests divided by
the total number of patients. Normalcy rate, a referral bias
independent estimate of specificity (33), was defined as the
proportion of patients with a low pretest likelihood of CAD
(,10%) who had negative test results. Mean values for
sensitivity, specificity and accuracy were calculated by combin-
ing the results of individual patient data from multiple studies.
Comparisons of sensitivity, specificity and accuracy were per-
formed using the standardized normal distribution test. Statis-
tical significance was defined at p , 0.05.
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Test Methodology
Dobutamine: pharmacology and mechanism of action. Do-
butamine is a synthetic catecholamine with a relatively short
plasma half-life of ;2 min due to rapid metabolization in the
liver to inactive metabolites (34,35). It has strong beta1-
receptor and mild alpha1- and beta2-receptor agonist activity.
When used at low dose (up to 10 mg/kg body weight per min),
marked inotropic effects (mediated by both alpha1- and beta1-
receptor stimulation) are encountered. These effects are ex-
tensively used for treatment of heart failure. When used at
high dose (20 to 40 mg/kg per min), heart rate is progressively
increased (mediated by beta1-receptor stimulation). Systemic
blood pressure increases only minimally because of an increase
in cardiac output and a decrease in systemic vascular resistance
because of peripheral vasoconstrictive effects (mediated by
alpha1-receptor stimulation) overwhelmed by vasodilative ef-
fects (mediated by beta2-receptor stimulation). In patients
without a sufficient increase in heart rate, the addition of
atropine has been proposed to further increase heart rate by its
vagolytic effects (14). As a result of the hemodynamic changes
there is an increase in oxygen demand. However, in myocardial
regions supplied by a coronary artery with a critical stenosis,
the increase in oxygen demand cannot be met by an adequate
increase in blood flow (36). Hence, regional ischemia develops
and causes regional wall motion abnormalities that can be
detected by two-dimensional echocardiography (5–32).
Protocol. Protocols for DSE vary from institution to insti-
tution, particularly with regard to dobutamine dose (range 20
to 40 mg/kg per min), atropine addition (range 0 to 2 mg) and
stage duration (range 2 to 8 min) (5–32,37). Usually, centers
that use lower peak doses of dobutamine use longer stage
durations and stop beta-adrenergic blocking agent treatment
more often before the test. To date, the most widely used
protocol uses dobutamine up to 40 mg/kg per min, with the
addition of atropine up to 1 mg (14).
According to this protocol, a rest electrocardiogram (ECG)
and two-dimensional echocardiogram are acquired, intrave-
nous access is secured, and dobutamine is then administered
intravenously by an infusion pump, starting at 5 or 10 mg/kg per
min for 3 min, increasing by 10 mg/kg per min every 3 min up
to a maximum of 40 mg/kg per min. In patients not achieving
85% of their theoretic maximal heart rate (220 beats/min
minus age for men, beats/min 200 minus age for women) and
without symptoms or signs of myocardial ischemia, atropine is
administered on top of the maximal dose of dobutamine,
starting with 0.25 mg intravenously and repeated up to a
maximum of 1.0 mg within 4 min, with continuation of
dobutamine infusion. Throughout dobutamine infusion, the
ECG (three leads) is continuously monitored and recorded (12
leads) at 1-min intervals. Blood pressure is measured and
recorded by sphygmanometry or automatic device every 3 min.
The echocardiogram is continuously monitored and recorded
on video or quad screen during the final minute of each
dobutamine (or atropine) stage and recovery. Reasons for
interruption of the test are severe or extensive new wall motion
abnormalities; horizontal or downsloping ST segment de-
pression .0.2 mV at an interval of 80 ms after the J point
compared with baseline; ST segment elevation .0.1 mV in
patients without a previous MI; severe angina; a symptomatic
reduction in systolic blood pressure $40 mm Hg from baseline;
hypertension (blood pressure $240/120 mm Hg); significant
tachyarrhythmias; and any serious side effect regarded as due
to dobutamine. A beta-blocker that can be injected intrave-
nously must be available to reverse the effects of dobutamine if
they do not revert spontaneously and quickly. Contraindica-
tions to DSE include critical aortic stenosis, hypertrophic
cardiomyopathy, uncontrolled hypertension, uncontrolled
atrial fibrillation, known severe ventricular arrhythmias and
electrolyte abnormalities (mainly hypokalemia) (38,39). The
addition of atropine is contraindicated in patients with narrow-
angle glaucoma, myasthenia gravis, obstructive uropathy or
obstructive gastrointestinal disorders.
Echocardiographic interpretation. For purposes of analy-
sis, the left ventricle is usually divided into the 16-segment
model recommended by the American Society of Echocardi-
ography (Fig. 1) (40). Although the quad screen format (with
rest, low and high dose and recovery images next to each other
in one screen) facilitates wall motion analysis, it is not a
prerequisite because videotape analysis seems to be as reliable
(41). Wall motion or thickening is reported according to an
arbitrary numerical classification: 1 5 normal, characterized by
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
DSE 5 dobutamine stress echocardiography
(echocardiographic)
ECG 5 electrocardiogram, electrocardiographic
LBBB 5 left bundle branch block
LVH 5 left ventricular hypertrophy
MI 5 myocardial infarction
Tc 5 technetium
Figure 1. Diagrams showing the 16 regional wall segments and
distribution of coronary perfusion. Left, Apical four-chamber view;
middle, apical two-chamber view; right, long-axis view. Dotted areas 5
left anterior descending coronary artery; crosshatched areas 5 left
circumflex coronary artery; solid areas 5 right coronary artery.
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a uniform increase in wall excursion and thickening; 2 5
hypokinesia, denoted by reduced (,5 mm) inward systolic wall
motion; 3 5 akinesia, is marked by an absence of inward
motion and thickening; 4 5 dyskinesia, indicated by systolic
thinning and outward systolic wall motion. Hypokinetic seg-
ments can be further classified as mild (2A) or severe (2B)
hypokinetic segments to refine the analysis. A normal stress
echocardiogram is defined by a uniform increase in wall motion
and systolic wall thickening, with a reduction in end-systolic
cavity area. A positive test is denoted by development of new
wall motion dyssynergy or by worsening of regional dyssynergy
in one or more segments. In patients with rest wall motion
abnormalities, use of the “biphasic” response (i.e., initial
improvement of dyssynergy at low dose followed by worsening
of dyssynergy at high dose) has improved detection of CAD
(42). More subtle criteria for positive test are tardokinesia
(delayed excursions) and relative failure to augment wall
thickening. These more subtle criteria should be used with
caution by unexperienced interpreters because too strict appli-
cation could lead to substantial loss in specificity (43). More-
over, isolated mild wall motion deterioration in mid- or basal
inferoposterior segments needs to be interpreted with caution
because these segments are known to be less specific for CAD
(43,44). Several investigators have reported (8,12,13,25) that
the inclusion of rest wall motion abnormalities in addition to
new or worsening wall motion abnormalities as a criteria for
positive test results in a gain in sensitivity without a loss in
specificity for the detection of CAD. However, the inclusion of
rest wall motion abnormalities as a criterion for CAD is
appropriate only in patients without a previous MI because in
patients with a previous MI, this diagnosis is nearly certain and
does not require further testing for this purpose.
Other possible dobutamine-induced markers of ischemia.
Abnormal left ventricular diastolic filling. Changes in diastolic
indexes are known to precede systolic changes and therefore
may be a more sensitive indicator of myocardial ischemia (45).
Despite the finding (46) that left ventricular filling is predom-
inantly mediated by a complex interaction of active myocardial
relaxation, passive filling properties and left atrial pressure,
one study clearly demonstrated (47) that during dobutamine
stress testing, an abnormal response of Doppler indexes of left
ventricular early filling (E velocity) is a more sensitive marker
for the detection of significant single-vessel disease than are
wall motion abnormalities. Other, confirmative publications
are needed to firmly establish the clinical utility of left ventric-
ular filling indexes.
Sinus node deceleration. Dobutamine stress-induced sinus
node deceleration, defined as an initial increase and subse-
quent decrease in heart rate with progressive dobutamine
infusion, occurs more often during dobutamine infusion than
during exercise (48). In a small group of patients, it was
reported (49) to be a specific marker of inferior wall ischemia,
as assessed by dobutamine perfusion scintigraphy. Currently,
there are no stress echocardiographic data reporting the
pathophysiology of isolated sinus node deceleration. Cardiac
slowing, in particular in combination with hypotension (see
later), may also result from a neurally mediated cardiovascular
vasodepressor reflex (50).
Mitral regurgitation. Low dose dobutamine is known to have
a beneficial effect on chronic mitral regurgitation, especially in
patients with left ventricular dysfunction (51,52). Although the
mechanism of this beneficial effect remains unclear, it may be
related to a decrease in afterload or mitral orifice size that
results from the vasodilatory and inotropic effects of dobut-
amine (53). It has been suggested (12) that the development of
new or worsening mitral regurgitation with stress doses of
dobutamine is related to ischemia and improves the sensitivity
of DSE for the detection of CAD. However, a study specifically
addressed to this subject reported (51) that in fact very few
patients developed new or worsening mitral regurgitation
during high dose dobutamine infusion, and there was no
association with stress-induced wall motion abnormalities.
Hypotension. Generally, dobutamine stress causes an in-
crease in cardiac output and a small reduction in systemic
vascular resistance (53,54), with a small increase in systolic
blood pressure as a net result (5–32). Although the pathophys-
iology of dobutamine stress-induced hypotension has not been
completely defined, theoretically, it may result from 1) an
inadequate increase in cardiac output to compensate for an
expected decrease in systemic vascular resistance; and 2) a
disproportionate decrease in systemic vascular resistance in the
presence of a normal increase in cardiac output. An inade-
quate increase in cardiac output may be due to inadequate
contractile reserve, severe ischemic left ventricular dysfunction
or left-sided obstructive heart disease. Dynamic left ventricular
cavity obliteration due to strong inotropic stimulation was
proposed as an important cause for reduced cardiac output
and hypotension (55), especially in patients with dehydration.
Later studies could not confirm this mechanism (56), and the
proposed bolus of saline before dobutamine (55,57) did not
prevent cavity obliteration in a canine model (58). The second
mechanism, a disproportionate decrease in systemic vascular
resistance, may be due to excessive sensitivity of the peripheral
circulation to beta2-receptor stimulation, increased beta2-
receptor density (deconditioned patients) or a neurally medi-
ated mechanism in which vigorous myocardial contraction
stimulates the intramyocardial mechanoreceptors, resulting in
sympathetic withdrawal and enhanced parasympathetic activity
(the Bezold-Jarisch reflex) (59). In contrast to exercise stress-
induced hypotension (60), all presently available data indicate
that there is no relation between ischemic left ventricular
systolic dysfunction (54,56,61,62) or angiographically detected
CAD (61) and dobutamine stress-induced hypotension.
ECG changes. Whereas ST segment changes are the hall-
mark of ischemia in exercise tests (2), they seem to have less
value during dobutamine stress. In an early study in patients
with mainly unstable angina and severe coronary lesions,
dobutamine stress-induced ST segment depression was de-
scribed as a highly accurate diagnostic test (63). However,
subsequent reports in stable patients with less severe lesions
could never confirm these data (7,12,29,64). Whether this is
due to misplacement of electrodes (because of the apical
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acoustic window), less stress (lower rate–pressure product than
for exercise tests) or other factors still needs to be established.
In contrast, as in exercise testing (65), dobutamine stress-
induced ST segment elevation in patients without a previous
MI was consistently reported to be associated with (severe)
coronary artery disease (63,64,66,67).
Feasibility and safety. In ;5% of patients, an inadequate
acoustic window precludes the performance of successful DSE
(37,68), although this proportion may underestimate the actual
number of patients with an inadequate acoustic window in an
unselected population. Furthermore, 10% of tests are nondi-
agnostic (absence of ischemic markers in submaximal tests)
(68,69) because of an insufficient hemodynamic response to
dobutamine–atropine administration or limiting side effects.
Noncardiac side effects (nausea, headache, chills, urgency and
anxiety) are usually well tolerated, without the need for test
termination. The most common cardiovascular side effects are
angina, hypotension and cardiac arrhythmias. Although angina
occurs in ;20% of patients (68,70), severe angina as a test end
point without accompanying new or worsening wall motion
abnormalities is rare. Dobutamine stress-induced hypotension
occurs, depending on its definition, in 5% to 37% of patients
(54,56,61,62,68,71): A $20-mm Hg decrease in systolic blood
pressure occurs in ;20% (54,61,71); severe, symptomatic
hypotension necessitating test termination occurs only rarely
(71). Arrhythmias are not uncommon (68,70), with frequent
premature atrial or ventricular contractions occurring in
;10% of patients and supraventricular or ventricular tachy-
cardias each occurring in ;4% of patients. Ventricular tachy-
cardias are usually nonsustained and have been attributed to
beta1-receptor stimulation and dobutamine-induced reduction
in plasma potassium concentrations (39). These arrhythmias
are more frequently encountered in patients with a history of
previous ventricular arrhythmias or baseline wall motion ab-
normalities (68). No study has reported an association between
the addition of atropine or new wall motion abnormalities and
ventricular tachycardias (68,70). On the basis of combined
diagnostic and safety reports on DSE (5–32,68–70), it can be
roughly estimated that ventricular fibrillation or MI occurs in 1
of 2,000 studies. These severe complications can occur up to
20 min after dobutamine withdrawal (69), and it has been
suggested (69) that in these patients, alpha1-mediated coro-
nary and systemic vasoconstriction might be paradoxically
exacerbated, not reversed, by beta-blocker administration.
Atropine intoxication, although generally requiring a dose of
atropine of at least 5 mg (72), has been reported in a few
patients receiving #1 mg of atropine (69). Fatal events were
not reported (5–32,68–70).
Intraobserver and interobserver agreement. Intraobserver
and interobserver agreement for ischemia within institutes as
reported in individual studies (6,7,20,23,25,31) ranged from
95% to 98% and from 92% to 96%, respectively. However, a
study specifically addressing interinstitutional agreement in
DSE between five centers (73) reported that abnormal or
normal results of DSE were agreed on by four or five of the five
centers in only 73% of patients. Agreement on the left anterior
descending territory (78%) was similar to that for the com-
bined right coronary and left circumflex territories (74%). For
specific segments, agreement ranged from 84% to 97% and
was highest for the basal anterior segment and lowest for the
basal inferior segment. Agreement was clearly higher in pa-
tients without CAD or with extensive CAD and was lower in
patients with limited echocardiographic image quality.
Diagnostic Accuracy
Detection of CAD. As with other tests for detection of
CAD, the diagnostic accuracy of DSE is expressed by its
sensitivity, specificity and accuracy. These indexes depend on
several technical factors, such as the definition of a positive test
and the threshold for defining significant CAD. In addition,
several characteristics of the patients studied may affect these
indexes, such as the presence or absence of MI, the number of
male patients, referral bias, the level of stress and the severity
(percent stenosis) and extent (number of diseased vessels) of
CAD in the referred cohort.
The reported sensitivity, specificity and accuracy for each of
28 published studies (5–32) are shown in Table 1. The overall
(weighted mean) sensitivity, specificity and accuracy of DSE
for a total of 2,246 patients was 80% (95% confidence interval
[CI] 78% to 82%), 84% (95% CI 82% to 86%) and 81% (95%
CI 79% to 83%), respectively (Fig. 2). When only the 17 largest
series from single centers were included (7,9–12,14,16,18–
21,26–28,30–32) (thus avoiding potential double counting of
previously included patients from the same center in an earlier
report), these respective numbers were, for a total of 1,454
patients, 81% (95% CI 79% to 84%), 85% (95% CI 82% to
87%) and 82% (95% CI 80% to 85%). The normalcy rate was
reported to be 92% (74).
From the results of the individual studies in Table 1 it
cannot be concluded that the addition of atropine improves the
diagnostic accuracy of DSE. However, in those studies in which
atropine was used, relatively many patients were taking a
beta-blocker and had mild CAD. Indeed, all studies directly
comparing DSE with versus without atropine (14,32) showed
an increase in sensitivity without a loss in specificity. These
results were recently confirmed by a study from the Mayo
Clinic (75) showing that the addition of atropine significantly
increased sensitivity, especially in patients taking a beta-
blocker and with milder forms of CAD.
The effect of the number of diseased coronary arteries was
assessed in 15 studies (5–8,12,16,20–23,25,26,28,31,32), for a
total of 897 patients. Mean sensitivity increased significantly
from 74% for single-vessel disease to 86% for double-vessel
disease and to 92% for triple-vessel disease (Fig. 3).
Different reports from center to center are most likely due
to the aforementioned factors. One of the most important
avoidable factors influencing test sensitivity is the use of
beta-blockers. These medications lower peak cardiac work
load and inotropic response during DSE (5,76) and thus have
the potential to lower the sensitivity of the test, especially when
atropine is not added to dobutamine (77). Investigators who
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compared study patients with versus without beta-blocker
therapy (13,18,25) consistently found that sensitivity was lower
in patients with beta-blocker therapy despite the finding that
patients taking beta-blockers generally have a higher preva-
lence of (extensive) CAD (13).
Bayesian analysis. Although values for sensitivity and
specificity have a useful role, the use of DSE in diagnostic
practice is to assist in the clinical recognition of CAD. In this
sense, tests are used to reclassify the initial clinical impression
of the probability of CAD into high, low and intermediate risk
subgroups. According to the Bayes theorem, the likelihood of
a positive test result is determined by the probability of CAD
in the patient studied, as well as the accuracy of the test (78).
In one report (79) that included 223 patients without a
previous MI, the study cohort was grouped into those with a
high (.80%), intermediate (10% to 80%) and low probability
(,10%) of CAD before and after DSE, and the ability of DSE
to restratify patients was analyzed. According to the pretest
likelihood of CAD, 68 patients (30%) were regarded as having
a “diagnostic” low or high probability of CAD. By application
of the Bayes theorem, DSE defined 121 patients (54%) as
being in the high or low posttest probability groups. Impor-
tantly, the accuracy of predicting CAD in the high probability
group and the absence of CAD in the low probability group
after DSE was excellent (87%).
Detection of disease in individual coronary arteries. The
coronary arteries and their branches supply different regions of
the left ventricular myocardium. Based on the known anatomic
relations between coronary arteries and various myocardial
regions, general guidelines have been developed for the assign-
Table 1. Diagnostic Accuracy of Dobutamine Stress Echocardiography As Reported in 28 Studies
Year
and
First
Author
(ref no.)
Protocol
No.
of
Pts
Men
(%)
MI
(%)
No
CAD
(%)
MVD
(%)
Beta-
Blocker
Cor Angio
WMA
Sens
(%)
Spec
(%)
Accuracy
(%)
Dobutamine
(mg/kg
per min)
Stage
Duration
(min)
% Diam
Stenosis Anal
1991
Sawada (5) 30 3 55 62 0 36 26 1 $ 50 Q New 89 85 87
Previtali (6) 40 5 35 86 3 20 34 2 $ 70 V New 68 100 74
Cohen (7) 40 3 70 100 27 27 50 2 $ 70 V New 86 95 89
1992
Salustri (8) 40* 3 52 73 27 29 33 1 $ 50 Q New 54 80 62
Martin (9) 40 3 40 95 35 38 NA 1 $ 50 V New 76 60 70
Segar (10) 30 3 85 61 NA 26 NA NA $ 50 Q New 95 82 92
Marcovitz (11) 30 3 141 60 29 23 33 1 $ 50 Q Any 96 66 89
Mazeika (12) 20 8 50 88 26 28 48 2 $ 70 V New 64 93 72
Salustri (13) 40 3 46 70 33 39 39 1 $ 50 Q New 57 78 65
McNeill (14) 40* 3 80 74 35 41 NA 1 $ 50 V New 70 88 78
1993
Marwick (15) 40 3 97 71 0 39 29 2 $ 50 Q Any 85 82 84
Gu¨nalp (16) 30 5 27 85 0 33 33 2 $ 50 V New 83 89 85
Forster (17) 40* 3 21 55 0 43 38 1 $ 50 V New 75 89 81
Marwick (18) 40 3 217 72 0 35 34 1 $ 50 Q Any 72 83 76
Hoffmann (19) 40* 2 60 77 0 20 35 2 $ 70 Q New 79 83 80
Previtali (20) 40 5 80 78 19 29 41 2 $ 50 V New 79 83 80
Takeuchi (21) 30 5 120 74 52 38 31 1 $ 50 Q Any 85 93 88
Baudhuin (22) 40 3 136 61 0 30 29 2 $ 50 Q Any 79 83 80
Cohen (23) 40 3 52 98 25 29 40 2 $ 70 V New 86 87 87
1994
Marwick (24) 40 3 86 70 0 35 40 1 $ 50 Q Any 54 83 64
Beleslin (25) 40 3 136 85 57 13 8 1 $ 50 Q New 82 76 82
Senior (26) 40 3 61 72 21 28 49 2 $ 50 V Any 93 94 93
Sochowski (27) 40 3 46 67 0 46 28 1 $ 50 V New 68 81 74
Ostojic (28) 40 3 150 83 51 13 11 1 $ 50 Q New 75 79 75
1995
Daoud (29) 30 3 76 58 37 15 55 1 $ 50 V Any 92 73 89
Dagianti (30) 40 5 60 79 0 58 25 2 $ 70 Q New 72 97 87
Ho (31) 40 3 54 85 41 21 67 NA $ 50 V New 93 73 89
1996
Pingitore (32) 40* 3 110 83 27 16 46 1 $ 50 Q New 84 89 85
*Atropine addition. Anal 5 analysis; CAD 5 coronary artery disease; Cor Angio 5 coronary angiography; Diam 5 diameter; MI 5 myocardial infarction; MVD 5
multivessel disease; NA 5 not available; Pts 5 patients; Q 5 (semi)quantitative; ref 5 reference; Sens 5 sensitivity; Spec 5 specificity; V 5 visual; WMA 5 wall motion
abnormality.
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ment of these myocardial regions to specific coronary arteries
(Fig. 1). It is therefore possible to infer disease of a given
coronary artery by noting the location of a wall motion
abnormality on echocardiography. Figure 4 summarizes the
sensitivity and specificity for the identification of disease in the
left anterior descending, left circumflex and right coronary
arteries. The mean reported (12,21,26,31) sensitivities were
72%, 55% and 76%, respectively, and the mean specificities
were 88%, 93% and 89%, respectively. The sensitivity for
detection of left circumflex disease was lower than that for left
anterior descending (p , 0.02) and right coronary disease (p ,
0.005). The lower sensitivity for detection of disease in the left
circumflex artery can be explained by the variation in coronary
anatomy (with a small circumflex territory in some patients)
and problems with resolution of the lateral wall endocardium
because of the parallel orientation of the wall and the ultra-
sound beam. To compensate for the variation in blood supply
of the posterior wall (by either the left circumflex or right
coronary artery, depending on their relative size) others
(6,11,12) divided the blood supply of the heart into two
systems: an anterior (left anterior descending coronary artery)
system and a posterior (left circumflex and right coronary
arteries) system. For these circulations, the mean reported
sensitivities were 75% and 73%, respectively, and the mean
specificities were 86% and 80%, respectively.
Identification of extensive CAD. An important goal of
noninvasive stress testing is the identification of patients with
left main or three-vessel CAD. Such patients could benefit
from revascularization from a prognostic point of view (80).
Patients with multivessel disease can be differentiated from
patients with single-vessel disease by detection of echocardio-
graphic abnormalities in two or more coronary territories.
Investigators who examined the prediction of multivessel dis-
ease by this method (5,7,12,15,18,26) consistently reported a
high specificity (range 90% to 100%). However, the sensitivity
of DSE for the prediction of multivessel disease varied mark-
edly from 8% to 71%. Several factors contribute to the
underestimation of multivessel disease: inadequate stress pro-
tocols, the premature cessation of stress because of the devel-
opment of limiting ischemia in one region, imperfect assign-
ment of myocardial regions to coronary arteries, collateral
circulations and anatomically significant but functionally non-
significant lesions. Recent reports have shown that DSE pro-
vides other, unique features to identify multivessel disease, by
measuring the ischemic threshold (10,81) and left ventricular
volume changes (82). Eventually, an algorithm based on
patient clinical characteristics, combined with the aforemen-
tioned indicators of multivessel disease may lead to improved
identification of multivessel disease.
Figure 2. Sensitivity, specificity and accuracy of DSE for
detection of CAD.
Figure 3. Sensitivity of DSE for detection of CAD by
number of diseased vessels.
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Patients with left bundle branch block or left ventricular
hypertrophy. The ability of noninvasive tests to diagnose or
localize CAD in patients with left bundle branch block (LBBB)
or left ventricular hypertrophy (LVH) has been disappointing.
Exercise-induced changes on the ECG are nondiagnostic in the
presence of LBBB (83) and lack specificity in the presence of
LVH, even in the absence of baseline ECG abnormalities (84).
Moreover, several scintigraphic studies (85,86) have reported
false positive results for detecting CAD in the presence of
LBBB (especially when exercise stress is used) and LVH,
resulting in a low specificity. Reports on the use of DSE in
patients with LBBB or LVH are scarce. One study (87) in 13
patients without a previous MI and LBBB reported a sensitiv-
ity of 80%, a specificity of 87% and an accuracy of 85%. A
study (84) in 28 patients with a history of hypertension and
(echocardiographically defined) LVH reported a sensitivity of
89%, a specificity of 100% and an accuracy of 93%. The latter
study reported that DSE was more specific (100% vs. 22%, p ,
0.0001) and accurate (93% vs. 54%, p , 0.0001) compared
with exercise electrocardiography. Although both DSE studies
reported excellent accuracies for the detection of CAD, these
small studies require confirmation from larger series to firmly
establish the diagnostic value of DSE in patients with LBBB or
LVH.
Comparison with other stress modalities in patients able to
exercise adequately. Exercise electrocardiography. Apart from
the special issues, discussed in the previous section of this
review, several studies directly compared DSE with exercise
electrocardiography in more heterogeneous patient groups. As
seen in Figure 5, pooled data from eight studies (8,12,20,23–
26,30) directly comparing DSE and exercise electrocardiogra-
phy in the same 560 patients show that the sensitivity (76% vs.
63%, p , 0.0001), specificity (88% vs. 64%, p , 0.0001) and
accuracy (79% vs. 63%, p , 0.0001) of DSE was clearly
superior. However, since most studies did not specify how
many patients were able to exercise adequately, were using
digoxin or had abnormal rest ECG results, these results do not
indicate that the routine exercise test should be replaced by
DSE. Especially in patients with a low pretest likelihood of
CAD and in men with normal results on the rest ECG it can be
anticipated that DSE will provide little incremental diagnostic
information in a cost-effective manner.
Exercise echocardiography. The diagnostic accuracy of DSE
has led to enthusiasm for its general use rather than its
particular use in patients unable to exercise adequately. How-
ever, exercise echocardiography can be performed as well in
these patients. As seen in Figure 6, pooled data from four
studies (23–25,30) directly comparing DSE and exercise echo-
Figure 4. Sensitivity (open bars) and specificity (hatched
bars) of DSE for detection of CAD in individual coronary
arteries. Numbers within bars indicate number of vessels.
Included in the analysis were patients with single-vessel and
multivessel CAD. LAD 5 left anterior descending coronary
artery; LCx 5 left circumflex coronary artery; RCA 5 right
coronary artery.
Figure 5. Sensitivity, specificity and accuracy of DSE
(open bars) versus exercise electrocardiography (hatched
bars) for detection of CAD.
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cardiography in the same 334 patients show that the sensitivity
(75% vs. 85%, p , 0.01) and accuracy (79% vs. 86%, p , 0.05)
of exercise echocardiography were significantly higher. It
should be emphasized that these differences were caused by
one particular study in which DSE showed low accuracy (24).
In that study a large number of DSE tests were submaximal
because a modest decline in systolic blood pressure was used as
a, not uncommon, end point, and a substantial number of the
study patients were using beta-blockers while atropine was not
added to dobutamine. It seems likely that in this patient
cohort, the previously described dobutamine–atropine proto-
col would have resulted in better diagnostic accuracy, probably
comparable to exercise echocardiography. However, the
choice for the latter in patients who are expected to exercise
adequately can be justified by better patient acceptance, fewer
unpleasant side effects and the complementary functional
information provided by exercise, such as duration of exercise,
increase in heart rate, blood pressure response and reproduc-
tion of symptoms.
Comparison with other stress modalities in patients unable
to exercise adequately. Dipyridamole echocardiography. In pa-
tients unable to perform adequate exercise, echocardiographic
imaging can also be performed with dipyridamole as a phar-
macologic stressor (36). In normal arteries dipyridamole, an
indirect coronary vasodilator (88), causes a three- to fivefold
increase in both subendocardial and subepicardial coronary
flow (89). However, in stenosed arteries this augmentation is
limited (depending on stenosis severity), creating flow hetero-
geneity. Echocardiographically detected functional evidence of
ischemia is not caused by marked changes in blood pressure or
heart rate (which change only minimally to moderately) but by
coronary steal—either “vertical” (subepicardium from suben-
docardium) (90) or “horizontal” (nonstenotic from stenotic
vessel territory) (91). As seen in Figure 7, pooled data from six
studies (9,13,20,27,28,30) directly comparing DSE and dipyr-
idamole echocardiography in the same 422 patients show that
DSE is more sensitive for the detection of CAD (73% vs. 65%,
p , 0.05), mainly because of a higher sensitivity in patients
with single-vessel disease. The specificity (82% vs. 89%) and
accuracy (76% vs. 72%) of the respective tests were not
significantly different. These results are not surprising because
dipyridamole creates primarily blood flow heterogeneity (not
detected by echocardiography) and “true” ischemia only in a
limited number of patients. Moreover, the detection of isch-
emia with dobutamine stress is facilitated by the improved
thickening of normal segments as opposed to decreased thick-
ening of ischemic segments, whereas dipyridamole has a lesser
effect on normal segments. However, recent reports (32,92)
have suggested that the addition of atropine to dipyridamole
increases the sensitivity of the dipyridamole test for the
Figure 6. Sensitivity (Sens), specificity and accuracy of DSE
(open bars) versus exercise echocardiography (hatched
bars) for detection of CAD. MVD 5 multivessel disease;
SVD 5 single-vessel disease.
Figure 7. Sensitivity, specificity and accuracy of DSE
(open bars) versus dipyridamole echocardiography
(hatched bars) for detection of CAD. Abbreviations as in
Figure 6.
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detection of CAD to a level comparable with dobutamine–
atropine stress echocardiography.
Radionuclide imaging. During dobutamine stress, coronary
blood flow to the vascular bed of a normal artery increases
dramatically, whereas perfusion through a stenosed artery may
change minimally. On the basis of this induction in regional
flow heterogeneity, the dobutamine stress test can also be
performed in conjunction with radionuclide perfusion imaging.
In four studies comparing DSE with dobutamine technetium-
99m (Tc-99m) imaging in 318 patients, sensitivity was 76%
versus 81%, specificity 85% versus 71% (p , 0.01) and
accuracy 80% versus 78% (Fig. 8). The finding that DSE is
more specific but may be less sensitive (especially in patients
with single-vessel disease) is in line with the “ischemic cascade”
theory (93), which states that perfusion abnormalities due to
limited coronary flow reserve precede echocardiographic and
ECG changes. Only two studies (with available angiographic
data) reported the diagnostic accuracy of DSE versus vasodi-
lator perfusion imaging. In one study (15) comparing DSE with
adenosine Tc-99m imaging in 97 patients, sensitivity was 85%
versus 86%, specificity 82% versus 71% and accuracy 84%
versus 80%. In another study (31) comparing DSE with
dipyridamole thallium-201 imaging in 54 patients, sensitivity
was 93% versus 98%, specificity 73% versus 73% and accuracy
89% versus 93%. Therefore, DSE and radionuclide perfusion
imaging seem to have comparable diagnostic accuracy, and the
choice of one test over the other can be based on patient
characteristics and the competence of the laboratory perform-
ing the test.
Patients after MI. The major goals of DSE in patients with
a previous MI are to assess infarct-related coronary artery
patency and to identify patients with multivessel CAD. Al-
though the first report on DSE was in patients after MI (4), few
studies have been specifically addressed to such patients.
Infarct-related coronary artery stenosis was assessed in four
studies (94–97) without use of the “biphasic” response (42,98).
Sensitivities, specificities and accuracies in these studies ranged
between 56% and 93%, 82% and 91% and 63% and 93%,
respectively (Table 2). The higher sensitivity found in the study
of Takeuchi et al. (94) might be explained by their definition of
a positive (ischemic) test. DSE was defined as positive if peak
wall motion score index was equal to or higher than that at the
rest study. In the other studies, DSE was defined as positive if
new or worsening wall motion abnormalities occurred. The
detection of significant coronary artery stenosis in patients with
rest wall motion abnormalities should be based on new or
worsening wall motion abnormalities occurring at any stage,
with use of the “biphasic” response (42,98). Thus, Takeuchi et
al. probably overestimated, and the other studies probably
underestimated, true sensitivity. Smart et al. (99) recently
reported in a large series of patients, with use of the “biphasic”
response, a sensitivity of 82%, a specificity of 80% and a
diagnositc accuracy of 82% for the detection of infarct-related
coronary artery stenosis. The presence of multivessel CAD in
Table 2. Diagnostic Dobutamine Stress Echocardiographic Studies in Patients With Myocardial Infarction
Year
First Author
(ref no.)
No. of
Pts
IRA
Prediction of MVD
Remote Ischemia $2 Coronary Territories
Sens Spec Sens Spec Sens Spec
1986 Berthe (4) 30 NA NA 85% 88% NA NA
1994 Takeuchi (94) 40 93% 91% NA NA NA NA
1995 Bigi (95) 121 70% NA 84% 93% NA NA
1996 Elhendy (96) 132 76% 85% 73% 88% 47% 89%
1997 Elhendy (97) 72 56% 82% 68% 93% 40% 96%
1997 Smart (99) 206 82% 80% 68% 97% NA NA
IRA 5 infarct-related artery; other abbreviations as in Table 1.
Figure 8. Sensitivity, specificity and accuracy of DSE versus
dobutamine technetium-99m perfusion imaging (hatched
bars) for detection of CAD. Abbreviations as in Figure 6.
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patients with a previous MI should ideally be based on an
ischemic response in two coronary vascular territories. How-
ever, an approach in which remote ischemia (ischemia de-
tected outside the infarct-related coronary artery territory) is
considered diagnostic for multivessel CAD also seems valid
because in most of these patients the infarct-related coronary
artery is also significantly narrowed. Several studies (4,95–97, 99)
assessed the value of DSE for the identification of multivessel
CAD by this latter criterion. Sensitivities, specificities and accu-
racies in these studies ranged between 68% and 85%, 88% and
97% and 81% and 87%, respectively (Table 2). Importantly, in
two of the cited studies (94,97) a direct comparison was made
between DSE and radionuclide imaging. In both studies DSE
was found to be as accurate as radionuclide imaging and even
showed a trend toward greater sensitivity.
Future Developments
At present, the major limitations of DSE are endocardial
border definition and subjective interpretation of stress-
induced wall motion abnormalities. Enhancement of border
definition (and thus interpretation) is currently under investi-
gation with gray-scale B-mode color encoding (100), intrave-
nous contrast agents (101), tissue Doppler interrogation (102),
tissue characterization techniques and backscatter analysis
(103). Eventually, the results of these investigations should
lead to improved automatic border detection and objective
(computerized), realistic criteria for wall motion abnormalities
diagnostic of CAD (43).
Conclusions
DSE is a feasible, safe and useful exercise-independent
stress modality for assessing the presence, localization and
extent of CAD. The diagnostic accuracy of DSE seems at least
comparable to other, competitive noninvasive stress modalities
used in patients with limited exercise capacity. New technical
developments are expected to further increase its strengths and
should make the interpretation of stress echocardiograms
more uniform and less subjective.
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